Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q3 2026, worth $2.18M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 14, 2026, 1:25 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Mar 13, 2025 | Mar 13, 2024 | Mar 17, 2023 | Mar 21, 2022 |
| Operating expenses | $19.8M | $15.4M | $16.4M | $14.9M | $7.73M |
| Research and development | $9.34M | $7.25M | $7.62M | $6.32M | $2.52M |
| Selling, general and administrative | $10.5M | $8.11M | $8.76M | $8.59M | $5.21M |
| Operating income | -$19.8M | -$15.4M | -$16.4M | -$14.9M | -$7.73M |
| Income tax | $1.72K | $1.70K | $2.45K | $30 | $1.65K |
| Net income | -$20.8M | -$15.0M | -$15.4M | -$14.3M | -$7.71M |
| EPS, basic | $-21.58 | $-1.61 | $-1.83 | $-1.73 | – |
| EPS, diluted | $-21.58 | $-1.61 | $-1.83 | – | – |
| Weighted shares, basic | 966.1K | 9.36M | 8.40M | 8.26M | – |
| Weighted shares, diluted | 966.1K | 9.36M | 8.40M | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Mar 13, 2025 | Mar 13, 2024 | Mar 17, 2023 | Mar 21, 2022 |
| Cash and equivalents | $8.51M | $5.79M | $13.4M | $9.63M | $39.1M |
| Short-term investments | – | – | – | $16.8M | – |
| Total current assets | $9.31M | $6.62M | $14.0M | $27.2M | $40.4M |
| Property, plant and equipment | – | – | $735 | $2.02K | $3.80K |
| Total assets | $9.31M | $7.34M | $14.9M | $28.1M | $40.6M |
| Accounts payable | $544.1K | $870.2K | $806.0K | $1.38M | $2.64M |
| Total current liabilities | $6.16M | $3.39M | $2.77M | $3.43M | $4.60M |
| Total liabilities | – | $3.39M | $2.85M | $3.43M | $4.68M |
| Shareholders' equity | $3.15M | $3.94M | $12.1M | $24.6M | $35.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Mar 13, 2025 | Mar 13, 2024 | Mar 17, 2023 | Mar 21, 2022 |
| Operating cash flow | -$14.8M | -$12.3M | -$13.4M | -$13.1M | -$11.3M |
| Capital expenditures | – | – | – | – | $3.85K |
| Free cash flow | – | – | – | – | -$11.3M |
| Stock-based compensation | $1.36M | $2.31M | $2.97M | $2.96M | $1.51M |
| Investing cash flow | – | – | $17.1M | -$16.4M | $447.7K |
| Financing cash flow | $17.5M | $4.75M | – | – | $48.3M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 13, 2026 | 153.6M | +8,671.5% | SEC |
| Aug 13, 2026 | 133.2M | +11,941.5% | SEC |
| May 15, 2026 | 113.2M | +606.2% | SEC |
| Mar 16, 2026 | 2.24M | −84.5% | SEC |
| Nov 11, 2025 | 1.75M | −82.8% | SEC |
| Aug 12, 2025 | 1.11M | −89.1% | SEC |
| May 12, 2025 | 16.0M | +87.8% | SEC |
| Mar 12, 2025 | 14.4M | +69.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.